Understanding emotions in people with multiple sclerosis
Emotions Recognition in Multiple Sclerosis
This study is trying to see if people with relapsing-remitting multiple sclerosis can still recognize positive emotions like healthy volunteers can.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Sponsor | Lille Catholic University Academic / other |
| Locations | 1 site (Lille) |
| Trial ID | NCT04804787 on ClinicalTrials.gov |
What this trial studies
This study compares multiple sclerosis patients with healthy volunteers to assess their ability to recognize positive emotions. It aims to determine if patients with relapsing-remitting multiple sclerosis can still recognize positive emotions despite known difficulties with negative emotions. The study employs behavioral assessments and neurophysiological measures, such as electrodermal activity, to gather comprehensive data on emotional recognition. Participants will undergo a series of tests and questionnaires to evaluate their emotional recognition capabilities.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 55 with relapsing-remitting multiple sclerosis and mild disability.
Not a fit: Patients with significant motor or cognitive impairments, previous neurological conditions, or psychiatric disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of emotional recognition in multiple sclerosis, potentially leading to better therapeutic strategies.
How similar studies have performed: While studies have indicated emotional recognition deficits in multiple sclerosis, this specific approach combining behavioral and neurophysiological measures is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female between 18 and 55 years old. * Understand and able to express themselves in French. * EXPERIMENTAL GROUP : * Relapsing-remitting form (RRMS) * With an EDSS \< 4 (Expanded Disability Status Scale) * No significant motor, cerebellar or somatosensory disorders of the upper limbs or visual disorders (EDSS specific parameter \<2) * No flare-up in the last 6 weeks * No corticosteroids taken in the last 4 weeks * CONTROL GROUP : * Lack of global cognitive deterioration (according to Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) standards). * Gender, age and education level matching to the multiple sclerosis patients * Understanding and signing the informed consent and information letter regarding participation in the study. * Benefiting from health insurance coverage. Exclusion Criteria: * Persons with previous neurological pathologies, head trauma with loss of consciousness, psychiatric pathologies, serious general affections, perceptive or dysarthric disorders preventing verbal communication or reading, * People with sensory disorders (visual and auditory) that interfere with the performance of neuropsychological tests; * Treatment with psychotropic drugs (except benzodiazepines and hypnotics). * Refusal to participate after clear and fair information about the study. * Major persons under guardianship, under judicial protection, persons deprived of liberty. * Pregnant or breastfeeding women
Where this trial is running
Lille
- Hôpital Saint-Vincent de Paul — Lille, France (Recruiting)
Study contacts
- Principal investigator: Bruno Lenne — Hôpital Saint Vincent de Paul, Lille
- Study coordinator: Amélie Lansiaux, MD, PhD
- Email: lansiaux.amelie@ghicl.net
- Phone: 03.20.22.52.69
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.